Comparar compuestos
Seleccione hasta 3 compuestos para comparar protocolos, mecanismos, criterios de valoración y hallazgos de seguridad en paralelo.
Peptijournal · Sermorelin vs Ipamorelin · https://peptijournal.com/compare?c=sermorelin,ipamorelin · Impreso
SermorelinIpamorelin
Mismo objetivo
01Protocol
Sermorelin
- Viales
- 5 / 10 mg
- Datos de dosis
- Referencia de laboratorio; no indicado
Ipamorelin
- Start
- 0.1 mg
- Range
- 0.1–0.3 mg
- Frequency
- 1–3× daily
- Cycle
- 8–12 weeks
- Vials
- 5 / 10 mg
02Quick calculator
Sermorelin
Ipamorelin
03Mechanism of action
Sermorelin
Sermorelin is the first 29 amino acids of GHRH, the shortest fully active fragment. It stimulates pituitary GHRH receptors to release GH.
Ipamorelin
Ipamorelin is a synthetic pentapeptide that releases growth hormone through the ghrelin (GH secretagogue) receptor, like GHRP-6. It was developed from a GHRP-1 series with the central Ala-Trp dipeptide removed.
04Study endpoints
Sermorelin
- Used intravenously as a diagnostic test for GH deficiency, though a normal response cannot rule out hypothalamic causes.
- In some prepubertal children with idiopathic GH deficiency, height velocity increased significantly over 12 months, with limited data to 36 months.
Ipamorelin
- In rat pituitary cells and in anaesthetised rats and conscious swine, GH-release potency and efficacy were similar to GHRP-6.
- In swine it did not change FSH, LH, prolactin or TSH, and unlike GHRP-6 and GHRP-2 it did not raise ACTH or cortisol across a wide dose range.
- In adult female rats, 15 days of treatment dose-dependently increased longitudinal bone growth (42 to up to 52 µm/day) without changing total IGF-I.
05Safety & regulatory findings
Sermorelin
- Was FDA-approved (Geref) but the branded product was discontinued; it is now mainly compounded or sold for research.
- Listed as prohibited in sport by the World Anti-Doping Agency.
Ipamorelin
- Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
- Listed as prohibited in sport by the World Anti-Doping Agency.
- The hormone-selectivity findings are preclinical. A human phase 2 postoperative-ileus trial found no significant difference in key or secondary efficacy analyses; it does not establish chronic GH-enhancement benefits or safety for this catalog presentation.